Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
|Articles|July 19, 2019
Validation of defocus tolerance of novel aberration-neutral hydrophobic acrylic monofocal IOL
Author(s)Julianne Mobilian
Eva Liang, MD, discusses the take-home message from her presentation at ASCRS 2019
Advertisement
Eva Liang, MD, discusses the take-home message from the presentation she delivered at the 2019 meeting of the
Advertisement
Related to this article
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
3
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
4
Women’s Health: Identifying dry eye in rheumatoid arthritis can make all the difference
5